

**SUBMITTAL TO THE BOARD OF SUPERVISORS
COUNTY OF RIVERSIDE, STATE OF CALIFORNIA**



**ITEM: 3.43
(ID # 28847)**

MEETING DATE:
Tuesday, December 16, 2025

FROM : RUHS-PUBLIC HEALTH

SUBJECT: RIVERSIDE UNIVERSITY HEALTH SYSTEM-PUBLIC HEALTH: Authorize Riverside University Health System-Public Health (RUHS-PH) to Submit the Grant Application to California Department of Public Health (CDPH) for Strengthening Hospital Acquired Infections (HAI) & Antimicrobial Resistance (AR) Program Capacity (SHARP 2) for the Period of Performance of July 1, 2025, Through July 31, 2027. All Districts [Total amount \$309,312. up to \$61,862 in additional compensation – 100% Federal]

RECOMMENDED MOTION: That the Board of Supervisors:


1. Authorize RUHS-PH to submit the ELC SHARP 2 Grant Application to the California Department of Public Health for the Hospital Acquired Infections (HAI)/Antimicrobial Resistance (AR) Testing and Surveillance (“Grant Agreement”) for a total aggregate amount of \$309,312 from July 1, 2025 through July 31, 2027; and
2. Authorize the Director of Public Health to sign the Grant Agreement, as approved as to form by County Counsel, once available by CDPH; and
3. Authorize the Director of Public Health, or designee, based on the availability of fiscal funding and approved as to form by County Counsel, to: (a) sign all certifications, assurances, or reports to implement the Grant Agreement (b) sign subsequent amendments to the Grant Agreement, including modifications to the statement of work, that stay within the intent of the Grant Agreement; and (c) sign subsequent amendments to the Grant Agreement that do not exceed the sum total of twenty percent (20%) of the total aggregate amount.

ACTION:A-30, Policy

MINUTES OF THE BOARD OF SUPERVISORS

On motion of Supervisor Spiegel, seconded by Supervisor Perez and duly carried, IT WAS ORDERED that the above matter is approved as recommended.

Ayes: Spiegel, Washington, Perez, and Gutierrez
Nays: None
Absent: Medina
Date: December 16, 2025
xc: RUHS-PH

Kimberly A. Rector
Clerk of the Board
By: 
Deputy

**SUBMITTAL TO THE BOARD OF SUPERVISORS COUNTY OF RIVERSIDE,
STATE OF CALIFORNIA**

FINANCIAL DATA	Current Fiscal Year:	,Next Fiscal Year:	Total Cost:	Ongoing Cost
COST	\$68,049	\$241,263	\$309,312	\$0
NET COUNTY COST	\$0	\$0	\$0	\$0
SOURCE OF FUNDS: 100% Federal			Budget Adjustment: No	
			For Fiscal Year: 25/26 – 27/28	

C.E.O. RECOMMENDATION: Approve

BACKGROUND:

Summary

The Strengthening Hospital Acquired Infections (HAI)/Antimicrobial Resistance (AR) Program also known as the SHARP grant is funded through the American Rescue Plan Act of 2021, P.L. 117-2 as program-initiated component funding under Project E: Emerging Issues of CK19-1904. These funds are broadly intended to provide critical resources in support of a broad range of healthcare infection prevention and control (IPC) activities and epidemiologic surveillance related activities to detect, monitor, mitigate, and prevent the spread of SARS-CoV-2/COVID-19 in healthcare settings. These funds may also reasonably address other conditions in healthcare settings, such as healthcare associated infections (HAIs) and antimicrobial resistance (AR), which rely upon the same fundamental IPC and epidemiologic surveillance approaches that are used to detect, monitor, mitigate, and prevent the spread of SARS-CoV-2/COVID-19 in healthcare settings. Moreover, the prevention of AR pathogens and improving the appropriate use of antibiotics helps to protect COVID patients from complications and potential comorbidities.

Impact on Residents and Businesses

Antimicrobial Resistance (AR) continues to be a global threat due to the increased number of pathogens reaching collectively 2.8 million infections and over 35,000 deaths annually. Increased prevalence of carbapenemas-producing organisms (CPO) is concerning due to their rapid spread through microbial gene transfer, limited treatment options, and high mortality. Furthermore, the CPOs are more transmissible than non-CPOs implying the need for stricter measures of infection control. Therefore, the detection of these organisms including carbapenemas producing enterobacteriaceae (CRE) and carbapenemase Pseudomonas aeruginosa (CPA) pathogens constitutes a high level of priority for Riverside County and Riverside University Public Health laboratory to tackle this problem.

Additional Fiscal Information

This is new funding in the amount of \$309,312 to support the laboratory and enhance testing capabilities. These funds will be used for testing supplies, subcontractor services, and staff salary. This funding is awarded to the laboratory by the California Department of Public Health.

**SUBMITTAL TO THE BOARD OF SUPERVISORS COUNTY OF RIVERSIDE,
STATE OF CALIFORNIA**

County Fiscal Year

Year	Amount
25/26	\$68,049
26/27	\$235,078
27/28	\$6,185
Total	\$309,312

Contract History and Price Reasonableness

This is a new award funding. Contract history includes SHARP allocation 2 for \$309,312. The grant application was submitted on February, 2, 2025.

The request before the Board today is to authorize the Public Health Director to sign the Grant Agreement once it becomes available. Additionally, RUHS-PH is requesting approval for the Public Health Director to be charged with the responsibility of administering and implementing the ELC SHARP 2 funding for RUHS-PH, including accepting additional funding from CDPH for the Program through June 30, 2035. This will allow RUHS-PH to streamline the approval process for future funding opportunities for the same Program.

ATTACHMENTS:

- ATTACHMENT A.** SHARP 2 Application
- ATTACHMENT B.** SHARP 2 Workplan
- ATTACHMENT C.** SHARP 2 Expenditure Spend Plan


Douglas Cordonez Jr.




12/8/2025

Tomás J. Aragón, MD, DrPH
Director and State Public Health Officer

Gavin Newsom
Governor

**ELC – Strengthening HAI/AR Program
SHARP 2 Applications
Due February 21, 2025**

Public Health Laboratory Name: Riverside University Healthcare System Public Health Laboratory

Date: February 2, 2025

Point of Contact: Syreeta Steele, Assistant Laboratory Director

Email & Phone Number: s.steele@ruhealth.org , 951-358-5070

Guidance for Appropriations

California's current surveillance for Antimicrobial Resistant (AR) pathogens relies on testing performed by local Public Health Laboratories (PHLs), the CDPH Microbial Diseases Laboratory (MDL), and the Washington Regional ARLN laboratory. This ELC SHARP 2 funding supplement will support continuation of AR surveillance in California via identification and screening activities for carbapenemase-producing organisms (CPOs) and *Candida auris*, and antimicrobial susceptibility testing for *Neisseria gonorrhoeae*.

CDPH priorities for local funding are to maintain current capacity for screening, with consideration for the following:

1. Greater need for testing in region (existence in an underserved area/proximity to underserved jurisdictions)
2. Capacity to serve as regional testing center for epi-linked and/or response testing
3. Local participation in screening, especially from influential facilities (ventilator-equipped skilled nursing facilities and long-term acute care hospitals)

CDPH has allocated approximately \$991,737.00 for local PHL support for the priorities listed above. The term of these funds ends July 31, 2027. This application will help us determine your current capacity and local jurisdiction's need for continuing funds to maintain HAI/AR testing.

1. Please describe in detail current and/or future HAI/AR test capacity for which your PHL is requesting funding support.

Current HAI/AR Test Capability and Capacity (where N/A, please note):

a) Instrumentation available (e.g. GeneXpert – include # of modules; ABI 7500 Fast DX; BD Max):

Instrument	# of Instruments
GeneXpert	16 modules
ABI 7500 Fast DX	1 instrument
Quantstudio 5	1 instrument
Quantstudio 7	1 instrument
BD Max	N/A
Culture-based AST platforms (e.g. Vitek2, Microscan, Sensititre, other):	N/A
Hologic Panther Fusion	1 instrument
Vitek MALDI-TOF	1 instrument
Bruker MALDI (MBT STAR®-Carba Kit)	1 instrument

b) Does your PHL currently perform colonization screening and/or identification of CPOs? (Yes/No):

No, RUHS PHL does not currently perform colonization screening or identification of CPOs; however, isolates can be confirmed to the species level using the Vitek MALDI-TOF. We are actively working to address this gap and will be launching our Antimicrobial Resistance Surveillance Program on February 24, 2025 beginning with one of the three medical facilities we have recruited thus far.

The AMR program will initially provide phenotypic testing for CRE/CRPA isolates using the HARDY NG-CARBA-5 and genotypic testing of CPO isolates and rectal swabs using the Cepheid GeneXpert CARBA-R assay. In the near future, we plan to culture CARBA-R positive specimens using CHROMagar, expand our phenotypic testing capabilities to include *Acinetobacter baumannii* isolates using the Bruker MALDI MBT STAR®-Carba assay and genotype *Acinetobacter baumannii* carbapenemases using molecular methods.

To support these efforts, we are requesting a temperature-controlled thermomixer to reduce the need for specimen transport between BSL-2 and BSL-3 laboratory space. Acquiring a thermomixer will improve workflow efficiency, reduce turnaround times, and help maintain the integrity of temperature-sensitive reagents and samples, ultimately enhancing the accuracy and reliability of test results.

We are also requesting reagents and media plates to validate CRAB using the Bruker MALDI MBT STAR®-Carba and subtyping via molecular methods. Additionally, we seek funding to support the expansion of testing services and the recruitment of 10 healthcare facilities into the RUHS Antimicrobial Resistance Program, which will focus on the surveillance of both CPOs and *Candida auris*. Expanding this program is essential for early detection, timely intervention, and the prevention of antimicrobial-resistant organism transmission within our healthcare network and the broader community.

a. If yes, screening and identification methods used for CPO (please include volumes performed per month):

- i. CRE: Cepheid GeneXpert Carba-R, Hardy NG-CARBA-5, Vitek MALDI-TOF
- ii. CRPA: Cepheid GeneXpert Carba-R, Hardy NG-CARBA-5, Vitek MALDI-TOF
- iii. CRAB: Cepheid GeneXpert Carba-R, Vitek MALDI-TOF

c) Does your PHL currently perform screening and/or identification for *C. auris*? (Yes/No):

No, RUHS PHL does not currently perform *C. auris* screening or identification. However, we are in the process of verifying *C. auris* isolates on the Vitek MALDI-TOF and colonization detection on the Hologic Panther Fusion.

We are requesting a benchtop pH meter and supplies to ensure reagent integrity for AMR surveillance, as well as Hologic Open Access Cartridges for screening of *C. auris* from skin swabs. Changes in pH in reagents used for PCR can affect the quality of results over time. It is critical to maintain stable pH levels in PCR reagents, pH drift can significantly compromise the reliability of pH-dependent reagents used in CPO and *C. auris* screening, potentially resulting in inaccurate outcomes and reduced test sensitivity and specificity. Traditionally, pH strips have been used for measurement; however, they are highly variable and do not provide the precise assessments required for accurate testing.

a. If yes, screening and identification methods used for *C. auris* (please include volumes performed per month):

N/A

d) Does your PHL currently perform screening, identification and AST using Etest for *Neisseria gonorrhoeae*? (Yes/No): **No**

- a. If yes, screening and identification methods used for *Neisseria gonorrhoeae* AST (please include volumes performed per month):

N/A

- b. Does your PHL perform any other methods to detect *N. gonorrhoeae* antibiotic resistance?

RUHS PHL does not perform any methods to detect *N. gonorrhoeae* antibiotic resistance.

New or Future AR Test Capability and Capacity

- e) How many local health care facilities (hospitals/clinics) send specimens to your PHL for CPO and *C. auris* confirmation and/or colonization screening?

Currently, RUHS PHL receives specimens for CPO (CRO) and *C. auris* confirmation from 5 local health care facilities. These specimens are then sent to the state for further confirmation.

Starting in March 2025, RUHS will expand its role by conducting surveillance screening for CPOs for local facilities. We already have 3 facilities that are interested in joining our surveillance program in addition to the previous 5 mentioned. Also, by summer 2025, RUHS PHL add additional CPO testing (ie. Chromoagar and STARCarba) and *C.auris* screening and identification for local facilities. The goal is to have at least 10 facilities submitting specimens for CPO and/or *C.auris*.

- f) What are your PHL's current annual volumes of send-outs for CPO confirmation and/or colonization screening?

In 2024, the RUHS PHL current annual volume of sendouts for CPO confirmation and/or colonization screening was 43 isolates.

- g) What are your PHL's current annual volumes of send-outs for *C. auris* confirmation and colonization screening?

In 2024, the RUHS PHL annual volume of sendouts for *C. auris* confirmation and/or colonization screening was 69 isolates.

- h) What instrumentation will your PHL need to bring on CPO or *C. auris* colonization screening or confirmatory testing?

We are in the process of validating the Vitek MALDI-TOF and Hologic Panther Fusion for *C. auris* identification, and the Bruker MALDI (MBT

STAR®-Carba Kit) for CRAB identification. No other equipment is necessary at this time.

Additional Information or Comments:

- 2. As an option to maintain a screening network for CROs and/or *C. auris* in California, is your PHL currently able to perform ELC-funded testing under a regional model for adjacent local health jurisdictions? If no, would this be an option in the future?**

Yes, starting in March 2025 we can perform necessary testing of CROs for adjacent local health jurisdictions using the GeneXpert Carba-R and the NG-Carba-5. In the future, we expect to provide the same services for *Candida auris* using the Vitek MALDI-TOF and Hologic Panther Fusion.

- 3. Please complete the attached workplan and budget and submit to CARLProgram@cdph.ca.gov with your proposal:**
- a. Attachment 1: SHARP Workplan Template
 - b. Attachment 2: HAI SHARP Expenditure Spend Plan

Attachment B - SHARP 2 Workplan

CDC- STRENGTHENING HAI/AR PROGRAM CAPACITY

Local Health Jurisdiction Name:	Riverside County Public Health Laboratory
Grant Number: CFDA #:93.323	

Project II: Antibiotic Resistance Laboratory Network (AR Lab Network)

Activity A1 Actions and Deliverables:

P.II Activity A1 (Required, if funded): Write N/A if not applicable

Sustain laboratory capacity to perform tier 1 CLIA-compliant organism identification, carbapenemase production testing, carbapenem-resistance mechanism testing, and routine confirmatory antimicrobial susceptibility testing (AST) on CRE/CRPA and carbapenem-resistant *Acinetobacter baumannii* (CRAB), as recommended by CDC. This includes one or more of the sub-activities.

- a. Expanding CRE genera tested.
- b. Applying the full AR Lab Network testing directory to every eligible isolate received.
- c. Recruiting additional facilities to submit CRE/CRPA isolates.
- d. Facilitate connections with clinical laboratories in the state or jurisdiction to solicit submission of CRAB isolates for testing at the state/local PHL.
- e. Testing additional organisms if clinical lab testing suggests carbapenemase production.

Activity A1 - Milestone 1	Activity A1: A. Expanding CRE genera tested.	
	Planned Milestone (Provide a title for this milestone)	Ongoing and NEW: Onboarding Bruker MALDI-TOF MBT Star Carba and CRAB PCR
	Implementation Plan (Bulleted items or brief sentences)	Purchase cartridges, media and QC materials for phenotypic and genotypic testing. Purchase ThermoMixer and accessories for testing in BSL-2 lab spaces Purchase pH meter to monitor small volume reagent stability Purchase Open Access Cartridges and primers and probes for validation
	Applicant capacity: What is the current capacity to perform this milestone?	We do not have a phenotypic test capable of detecting hydrolysis of carbapenemases. We have purchased a Bruker MALDI and have an in-house Hologic Panther and ABI 7500 (and equivalent).

	Expected Achieve By Date <i>(select from drop down)</i>	12/31/2025
--	---	------------

Activity A1 - Milestone 2	Activity A1: B. Applying the full AR Lab Network testing directory to every eligible isolate received.	
	Planned Milestone (Provide a title for this milestone)	N/A
	Implementation Plan (Bulleated items or brief sentences)	
	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

Activity A1 - Milestone 3	Activity A1: C. Recruiting additional facilities to submit CRE/CRPA isolates.	
	Planned Milestone (Provide a title for this milestone)	NEW: RUHS PHL plans to recruit at least 10 facilities to the Antimicrobial Resistance Surveillance program.
	Implementation Plan (Bulleated items or brief sentences)	Specimen will be analyzed using the Vitek MALDI-TOF bioanalyzer, NG-CARBA-5, Bruker MALDI with MBL Star Carba and Cepheid GeneXpert with the Carba-R kit.
	Applicant capacity: What is the current capacity to perform this milestone?	We have verified Cepheid GeneXpert with the Carba-R kit and NG-CARBA-5. Vitek MALDI was already validated in house. We currently are onboarding 3 facilities.
	Expected Achieve By Date <i>(select from drop down)</i>	7/1/2027

CDC- STRENGTHENING HAI/AR PROGRAM CAPACITY

Local Health Jurisdiction Name:	Riverside County Public Health Laboratory
Grant Number: CFDA #:93.323	

Project II: Antibiotic Resistance Laboratory Network (AR Lab Network)

Activity A3 Actions and Deliverables:
 P.II Activity A3 (**Required**):

Collaborate and share information with AR Coordinators to facilitate communication laboratory on specimen submissions, test reporting, communication with LHJ epidemiologists, and facilities as needed.

Activity A3 -	Activity A3: Collaborate and share information with AR Coordinators to facilitate communication laboratory on specimen submissions, test reporting, communication with LHJ epidemiologists, and facilities as needed.	
	Planned Milestone (Provide a title for this milestone)	NEW: Lab Web Portal Data Analytics
	Implementation Plan (Bulleted items or brief sentences)	Develop data analytics to provide dashboards and give access to partners using Laboratory Web Portal
	Applicant capacity: What is the current capacity to perform this milestone?	None
	Expected Achieve By Date (select from drop down)	12/31/25

CDC- STRENGTHENING HAI/AR PROGRAM CAPACITY

Local Health Jurisdiction Name:	Riverside County Public Health Laboratory
Grant Number: CFDA #:93.323	

Project II: Antibiotic Resistance Laboratory Network (AR Lab Network)

Activity A5 Actions and Deliverables:

P.II Activity A5 (**Required**):

Advance electronic information exchange implementation. Address **all** of the sub-activities in the workplan.

- a. Identify a laboratory point of contact that will work with CDPH to ensure data exchange for timely reporting to submitting facilities, state or local public health laboratories, epidemiologists, regional AR prevention partners, and CDC for all funded AR testing.
- b. Integrate new tests in the laboratory LIMS system for accessioning and reporting.
- c. Ensuring adequate infrastructure for electronic reporting of test results to state and local HAI/AR Programs and submitters.
- d. If funding is available, work towards transitioning to HL7 messaging to report to CalREDIE and CDC for all AR Lab Network Testing.

Activity A5 - Milestone 1	Activity A5: A. Identify a laboratory point of contact that will work with CDPH to ensure data exchange for timely reporting to submitting facilities, state or local public health laboratories, epidemiologists, regional AR prevention partners, and CDC for all funded AR testing	
	Planned Milestone (Provide a title for this milestone)	N/A
	Implementation Plan (Bulleeted items or brief sentences)	
	Applicant capacity: What is the current capacity to perform this milestone?	

	Expected Achieve By Date <i>(select from drop down)</i>	
--	---	--

Activity A5 - Milestone 2	Activity A5: B.Integrate new tests in the laboratory LIMS system for accessioning and reporting.	
	Planned Milestone <i>(Provide a title for this milestone)</i>	NEW: Implementation of test is LIS and Laboratory Web Portal (LWP)
	Implementation Plan <i>(Bulleated items or brief sentences)</i>	Once new tests are validated, the LIMS administrator will add the tests to the EPIC Beaker LIS for diagnostic testing and LWP for surveillance testing.
	Applicant capacity: What is the current capacity to perform this milestone?	None
	Expected Achieve By Date <i>(select from drop down)</i>	3/1/2026

Activity A5 - Milestone 3	Activity A5: C. Ensure adequate infrastructure for electronic reporting of test results to state and local HAI/AR Programs and submitters.	
	Planned Milestone <i>(Provide a title for this milestone)</i>	ONGOING: Reporting to epidemiologists
	Implementation Plan <i>(Bulleated items or brief sentences)</i>	The LIMS administrator will ensure IT infrastructure is built for submissions and timely reporting to submitting facilities and epidemiologists.
	Applicant capacity: What is the current capacity to perform this milestone?	None
	Expected Achieve By Date <i>(select from drop down)</i>	3/1/2026

Activity A5 - Milestone 3	Activity A5: D. If funding is available, work towards transitioning to HL7 messaging to report to CalREDIE and CDC for all AR Lab Network Testing.	
	Planned Milestone (Provide a title for this milestone)	NEW: Reporting by HL7 via LWP
	Implementation Plan (Bulleled items or brief sentences)	The LIMS administrator will ensure IT infrastructure is built timely reporting to submitting facilities and epidemiologists (through the CalREDIE system) for new tests that will be offered.
	Applicant capacity: What is the current capacity to perform this milestone?	None
Expected Achieve By Date (select from drop down)	5/1/2026	

CDC- STRENGTHENING HAI/AR PROGRAM CAPACITY

Local Health Jurisdiction Name:	Riverside County Public Health Laboratory
Grant Number: CFDA #:93.323	

Project II: Antibiotic Resistance Laboratory Network (AR Lab Network)

Activity A6 Actions and Deliverables:

P.II Activity A6 (Required, if funded): **CPO COLONIZATION SCREENING**. Write "N/A" if not applicable

Provide laboratory support for state-led epidemiologic investigations and HAI/AR prevention efforts focused on **screening for targeted AR threats** (e.g., carbapenemase-producing organisms [CPOs], pan-resistant organisms) by performing CDC-recommended assay(s), including molecular tests to detect colonization with CPOs. Regional labs may use funding to expand capacity for this testing. If including this activity in the workplan, address all of the sub-activities.

- a. Work with AR Coordinators and HAI/AR Programs to facilitate collection and transportation of specimens for colonization testing to ensure timely testing of specimens.
- b. Provide advice to healthcare facilities and personnel on the collection and transportation of specimens.
- c. Test and report results to the jurisdictional public health department and submitting healthcare facility within **two working days of specimen receipt**.
- d. Submit colonization testing data to AR Coordinators monthly and **submit reports of positive screening results as alerts within 24 hours**.
- e. Provide additional culture work-up of positive CPO specimens received (if proposed), or send specimens to CDPH for additional testing.

Activity A6 - Milestone 1	Activity A6: A. Work with AR Coordinators and HAI/AR Programs to facilitate collection and transportation of specimens for colonization testing to ensure timely testing of specimens.	
	Planned Milestone (Provide a title for this milestone)	ONGOING: Collection and transportation of specimens
	Implementation Plan	Health Information and Community Outreach Manager (COM) to work with AR

	(Bulleted items or brief sentences)	coordinator
	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date (select from drop down)	

Activity A6 - Milestone 2	Activity A6: B . Provide advice to healthcare facilities and personnel on the collection and transportation of specimens.	
	Planned Milestone (Provide a title for this milestone)	ONGOING: Outreach
	Implementation Plan (Bulleted items or brief sentences)	Health Information and Community Outreach Manager will register new facilities in Lab Web Portal to facilitate submission and education of upcoming testing.
	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date (select from drop down)	

Activity A6 - Milestone 3	Activity A6: C. Test and report results to the jurisdictional public health department and submitting healthcare facility within two working days of specimen receipt.	
	Planned Milestone (Provide a title for this milestone)	ONGOING: Reporting to submitters and local epidemiologist
	Implementation Plan (Bulleted items or brief sentences)	LIS administrator will ensure reporting to submitter and local epidemiologist is active.

	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

Activity A6 - Milestone 4	Activity A6: D. Submit colonization testing data to AR Coordinators monthly and submit reports of positive screening results as alerts within 24 hours.	
	Planned Milestone <i>(Provide a title for this milestone)</i>	ONGOING: Reporting to CDPH
	Implementation Plan <i>(Bulleted items or brief sentences)</i>	LIMS administrator will ensure reporting to CDPH.
	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

Activity A6 - Milestone 5	Activity A6: E. Provide additional culture work-up of positive CPO specimens received (if proposed), or send specimens to CDPH for additional culture-based testing.	
	Planned Milestone <i>(Provide a title for this milestone)</i>	ONGOING: Culture and ID
	Implementation Plan <i>(Bulleted items or brief sentences)</i>	Culture and identification by MALDI-TOF will be performed. Subsequently, a phenotypic test will be performed for confirmation.

CDC- STRENGTHENING HAI/AR PROGRAM CAPACITY

Local Health Jurisdiction Name:	Riverside County Public Health Laboratory
Grant Number: CFDA #:93.323	

Project II: Antibiotic Resistance Laboratory Network (AR Lab Network)

Activity A7 Actions and Deliverables:

P.II Activity A7 (Required, if funded): Write "N/A" if not applicable. **NOTE: This activity is low priority for funding through SHARP 2**

Perform whole-genome sequencing (WGS) for HAI/AR pathogens to support national AR containment priorities in the region. In coordination with CDC, laboratories will support AR Lab Network priorities and epidemiologic investigations in state or jurisdiction. If including this activity in the workplan, address all of the sub-activities.

- a. Demonstrate sequencing capacity in adherence with CDC guidance for minimum quality requirements.
- b. Describe a plan to use bioinformatics tools to perform quality assessment and analyze sequence data.
- c. Implement WGS for HAI/AR pathogens in adherence with CDC guidance for priorities.
- d. Work with CDPH to utilize cloud computing and bioinformatic pipelines to facilitate data sharing and standardization. Submit sequencing data to National Center for Biotechnology Information (NCBI) for public posting and report sequencing IDs (per CDC guidance) and AR Lab Network isolate IDs to CDPH for reporting to CDC (or CDC directly once reporting mechanism is in place)

Activity A7 - Milestone 1	Activity A7: A. Demonstrate sequencing capacity in adherence with CDC guidance for minimum quality requirements.	
	Planned Milestone (Provide a title for this milestone)	N/A
	Implementation Plan (Bulleeted items or brief sentences)	

	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

Activity A7 - Milestone 2	Activity A7: B . Describe a plan to use bioinformatics tools to perform quality assessment and analyze sequence data.	
	Planned Milestone <i>(Provide a title for this milestone)</i>	N/A
	Implementation Plan <i>(Bulleated items or brief sentences)</i>	
	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

Activity A7 - Milestone 3	Activity A7: C . Implement WGS for HAI/AR pathogens in adherence with CDC guidance for priorities.	
	Planned Milestone <i>(Provide a title for this milestone)</i>	N/A
	Implementation Plan <i>(Bulleated items or brief sentences)</i>	
	Applicant capacity: What is the current capacity to perform this milestone?	

	Expected Achieve By Date <i>(select from drop down)</i>	
--	---	--

Activity A7 - Milestone 4	Activity A7: D. Work with CDPH to utilize cloud computing and bioinformatic pipelines to facilitate data sharing and standardization. Submit sequencing data to National Center for Biotechnology Information (NCBI) for public posting and report sequencing IDs (per CDC guidance) and AR Lab Network isolate IDs to CDPH for reporting to CDC (or CDC directly once reporting mechanism is in place)	
	Planned Milestone (Provide a title for this milestone)	N/A
	Implementation Plan (Bulleated items or brief sentences)	
	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

CDC- STRENGTHENING HAI/AR PROGRAM CAPACITY

Local Health Jurisdiction Name:	Riverside County Public Health Laboratory
Grant Number: CFDA #:93.323	

Project II: Antibiotic Resistance Laboratory Network (AR Lab Network)

Activity A9 Actions and Deliverables:

P.II Activity A9 (Required, if funded): Write "N/A" if not applicable

Increase or sustain laboratory capacity to perform *C. auris* colonization testing to support surveillance activities and outbreak investigations occurring within the state or local jurisdiction in the context of COVID-19. Regional labs may use funding to expand capacity for this testing. If including this activity in the workplan, address all of the sub-activities.

- a. Coordinate with AR Coordinators to transport collection swabs to healthcare facilities where swabbing for colonization testing will take place.
- b. Provide advice to healthcare facility laboratories on the collection and transportation of specimens.
- c. Test and report results to the jurisdictional public health department and submitting healthcare facility in timeframe consistent with CDC guidance.
- d. Submit colonization testing data to AR Coordinators monthly, and positive screening results to AR Coordinators within 24 hours.

Activity A9 - Milestone 1	Activity A9: A. Coordinate with AR Coordinators to transport collection swabs to healthcare facilities where swabbing for colonization testing will take place.	
	Planned Milestone (Provide a title for this milestone)	ONGOING: Collection and transportation of specimens
	Implementation Plan (Bulleted items or brief sentences)	Health Information and Community Outreach Manager to work with AR coordinator. Health Information and Community Outreach Manager will coordinate specimen submission frequency with County partners and coordinate County courier for transportation of specimens

	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

Activity A9 - Milestone 2	Activity A9: B. Provide advice to healthcare facility laboratories on the collection and transportation of specimens.	
	Planned Milestone <i>(Provide a title for this milestone)</i>	ONGOING: Outreach
	Implementation Plan <i>(Bulleated items or brief sentences)</i>	Health Information and Community Outreach Manager will develop plan and start registering facilities in lab web portal to facilitate submission and education of upcoming testing that will go live.
	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

Activity A9 - Milestone 3	Activity A9: C. Test and report results to the jurisdictional public health department and submitting healthcare facility in timeframe consistent with CDC guidance.	
	Planned Milestone <i>(Provide a title for this milestone)</i>	NEW: RUHS PHL plans to recruit at least 10 facilities to the Antimicrobial Resistance Surveillance program. Reporting to submitters and local epidemiologist.
	Implementation Plan <i>(Bulleated items or brief sentences)</i>	Once test is validated, the LIMS administrator will ensure reporting to submitter and local epidemiologist is active. Expand Candida auris on Hologic Panther Fusion to additional faciities. -Purchase reagents and materials for <i>C. auris</i> colonizaton screening

	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

Activity A9 - Milestone 4	Activity A9: D. Submit colonization testing data to AR Coordinators monthly, and positive screening results to AR Coordinators within 24 hours.	
	Planned Milestone <i>(Provide a title for this milestone)</i>	ONGOING: Reporting to CDPH
	Implementation Plan <i>(Bulleted items or brief sentences)</i>	Once test is validated, the LIMS administrator will ensure reporting to CDPH is active.
	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

CDC- STRENGTHENING HAI/AR PROGRAM CAPACITY

Local Health Jurisdiction Name:	Riverside County Public Health Laboratory
Grant Number: CFDA #:93.323	

Project II: Antibiotic Resistance Laboratory Network (AR Lab Network)

Activity A10 Actions and Deliverables:

P.II Activity A10 (Required, if funded): Write "N/A" if not applicable.

Increase or sustain laboratory capacity for N. gonorrhoeae gradient strip AST using to monitor cases of concern (e.g., suspected treatment failures), cases with prevalent susceptibility and to expand the potential to capture emerging resistance. If including this activity in the workplan, address all of the sub-activities.

- a. Implement CLIA compliant procedures to recover GC isolates from genital and extragenital specimens (including pharyngeal specimens) and conduct Etest for azithromycin, ceftriaxone, cefixime on GC isolates recovered from these specimens in accordance with CDC guidance.
- b. Provide specimen collection and/or transport materials to submitters and provide training to submitters for initial culture of N. gonorrhoeae based on the acceptable specimen types in their validated SOPs.
- c. Enroll in the semi-annual Proficiency Test program provided by the Wisconsin State Laboratory of Hygiene.
- d. Send Etest AST results back to submitters with a turn-around-time of 7 to 10 days. Submit alert data to AR Coordinators within 24 hours and submit summary data to AR Coordinators monthly.
- e. If concerning resistance is identified, conduct whole genome sequencing and molecular investigations of identified strains (optional) or send isolate to CDC or regional AR Laboratory.

Activity A10 - Milestone 1	Activity A10: A. Implement CLIA compliant procedures to recover GC isolates from genital and extragenital specimens (including pharyngeal specimens) and conduct Etest for azithromycin, ceftriaxone, cefixime on GC isolates recovered from these specimens in accordance with CDC guidance.	
	Planned Milestone (Provide a title for this milestone)	N/A

	Implementation Plan (Bulleed items or brief sentences)	
	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date (select from drop down)	

Activity A10 - Milestone 2	Activity A10: B. Provide specimen collection and/or transport materials to submitters and provide training to submitters for initial culture of N. gonorrhoeae based on the acceptable specimen types in their validated SOPs.	
	Planned Milestone (Provide a title for this milestone)	N/A
	Implementation Plan (Bulleed items or brief sentences)	
	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date (select from drop down)	

Activity A10 - Milestone 3	Activity A10: C . Enroll in the semi-annual Proficiency Test program provided by the Wisconsin State Laboratory of Hygiene (WSLH).	
	Planned Milestone (Provide a title for this milestone)	N/A
	Implementation Plan (Bulleed items or brief sentences)	

	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

Activity A10 - Milestone 4	Activity A10: D. Send Etest AST results back to submitters with a turn-around-time of 7 to 10 days. Submit alert data to AR Coordinators within 24 hours and submit summary data to AR Coordinators monthly.	
	Planned Milestone <i>(Provide a title for this milestone)</i>	N/A
	Implementation Plan <i>(Bulleted items or brief sentences)</i>	
	Applicant capacity: What is the current capacity to perform this milestone?	
	Expected Achieve By Date <i>(select from drop down)</i>	

Activity A10 - Milestone 5	Activity A10: E. Send isolates showing resistance of concern to CDPH for additional analysis.	
	Planned Milestone <i>(Provide a title for this milestone)</i>	N/A
	Implementation Plan <i>(Bulleted items or brief sentences)</i>	

